DelNova is developing proprietary therapies by leveraging advances in drug delivery technology. They have identified an anticholinesterase class of drugs as a means of accelerating muscle recovery by indirectly increasing the neurotransmitter deficit caused by botulinum toxin.

Biotechnology

Delivery

Health Care

Staffing & Recruiting

Delnova

Delnova's headquarters in Illinois City, IL, United States

Mary Gardner

Hannah Roddy

Dimas Jiménez

Steven Yoelin

Sameer B. Shah

Edward A. Ogunro

Daniel M. Bradbury

Kurt C. Gunter

Patricia S. Walker

Randall D. Ostroff

Michael B. Chancellor

Pradeep Tyagi

The Scientific Team at DelNova is responsible for researching and developing novel drug delivery systems based on anticholinesterase compounds to enhance muscle recovery. This team collaborates to design experiments, analyze data, and guide the formulation of therapies that counteract the neurotransmitter deficits caused by botulinum toxin.

Scientific Team

The Leadership Team at DelNova, comprising the CEO and Founder, Chief Scientist, and Chief Medical Strategist, oversees the strategic direction, scientific research, and clinical development of proprietary therapies leveraging advanced drug delivery technologies, specifically targeting muscle recovery post-botulinum toxin.

Leadership Team

Delnova

Org chart

Board & advisors

Teams

Scientific Team

Leadership Team

Offices

Delnova

Org chart

Board & advisors

Teams

Scientific Team

Leadership Team

Offices

Related companies